In the first round, as for the S3 statement (“FGF23 measurement is considered necessary for the diagnosis and initiation of treatment of hypophosphatemia”), the same percentage of respondents (41.2%) expressed strong and moderate agreement, with a minority of respondents (17.6%) indicating no agreement. Here, FGF23 is linked to hypophosphatemia.